Tamoxifen: Using pharmacogenetics to rediscover an old drug

A. H. Kamal, Matthew P. Goetz

Research output: Contribution to journalArticlepeer-review


Tamoxifen can be considered a classic 'pro-drug', requiring metabolic activation to elicit pharmacological activity. Our findings suggest that both genetic and drug-induced factors that alter CYP2D6 enzyme activity influence the clinical response to tamoxifen. Given the small differences in disease-free survival comparing tamoxifen to third-generation aromatase inhibitors, knowledge of the genetic and environmental factors that influence CYP2D6 enzyme activity may provide a robust tool to individualize the hormonal therapy to breast cancer.

Original languageEnglish (US)
Article numbere20
JournalBreast Cancer Online
Issue number10
StatePublished - Oct 2007


  • Aromatase inhibitors
  • Breast cancer
  • Endocrine therapy
  • Estrogen receptor
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Oncology(nursing)
  • Cancer Research


Dive into the research topics of 'Tamoxifen: Using pharmacogenetics to rediscover an old drug'. Together they form a unique fingerprint.

Cite this